Suppr超能文献

抗体通过不同的变构途径增强因子 VIIa 的活性。

Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways.

机构信息

Novo Nordisk A/S, Novo Nordisk Park, Måløv, Denmark.

出版信息

J Biol Chem. 2012 Mar 16;287(12):8994-9001. doi: 10.1074/jbc.M111.312330. Epub 2012 Jan 24.

Abstract

In the absence of its cofactor tissue factor (TF), coagulation factor VIIa (FVIIa) predominantly exists in a zymogen-like, catalytically incompetent state. Here we demonstrate that conformation-specific monoclonal antibodies (mAbs) can be used to characterize structural features determining the activity of FVIIa. We isolated two classes of mAbs, which both increased the catalytic efficiency of FVIIa more than 150-fold. The effects of the antibodies were retained with a FVIIa variant, which has been shown to be inert to allosteric activation by the natural activator TF, suggesting that the antibodies and TF employ distinct mechanisms of activation. The antibodies could be classified into two groups based on their patterns of affinities for different conformations of FVIIa. Whereas one class of antibodies affected both the K(m) and k(cat), the other class mainly affected the K(m). The antibody-induced activity enhancement could be traced to maturation of the S1 substrate binding pocket and the oxyanion hole, evident by an increased affinity for p-aminobenzamidine, an increased rate of antithrombin inhibition, an increased rate of incorporation of diisopropylfluorophosphate, and an enhanced fraction of molecules with a buried N terminus of the catalytic domain in the presence of antibodies. As demonstrated by site-directed mutagenesis, the two groups of antibodies appear to have overlapping, although clearly different, epitopes in the 170-loop. Our findings suggest that binding of ligands to specific residues in the 170-loop or its spatial vicinity may stabilize the S1 pocket and the oxyanion hole, and they may have general implications for the molecular understanding of FVIIa regulatory mechanisms.

摘要

在缺乏辅因子组织因子(TF)的情况下,凝血因子 VIIa(FVIIa)主要以酶原样、无催化活性的状态存在。在这里,我们证明了可以使用构象特异性单克隆抗体(mAbs)来表征决定 FVIIa 活性的结构特征。我们分离出两类 mAbs,它们都使 FVIIa 的催化效率提高了 150 多倍。抗体的作用在一种已被证明对天然激活剂 TF 的变构激活无反应的 FVIIa 变体中得以保留,这表明抗体和 TF 采用不同的激活机制。这些抗体可以根据它们对 FVIIa 不同构象的亲和力模式分为两类。一类抗体影响 K(m)和 k(cat),而另一类主要影响 K(m)。抗体诱导的活性增强可追溯到 S1 底物结合口袋和氧阴离子孔的成熟,这表现在对 p-氨基苯甲脒的亲和力增加、抗凝血酶抑制率增加、二异丙基氟磷酸酯掺入率增加以及在抗体存在下具有埋藏的催化结构域 N 末端的分子分数增加。通过定点突变,两组抗体似乎在 170 环中具有重叠但明显不同的表位。我们的发现表明,配体与 170 环或其空间附近的特定残基的结合可能稳定 S1 口袋和氧阴离子孔,这可能对 FVIIa 调节机制的分子理解具有普遍意义。

相似文献

1
Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways.
J Biol Chem. 2012 Mar 16;287(12):8994-9001. doi: 10.1074/jbc.M111.312330. Epub 2012 Jan 24.
2
Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.
J Biol Chem. 2020 Jan 10;295(2):517-528. doi: 10.1074/jbc.RA119.009183. Epub 2019 Dec 4.
3
Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa.
FEBS J. 2009 Jun;276(11):3099-109. doi: 10.1111/j.1742-4658.2009.07028.x. Epub 2009 Apr 23.
5
Evolutionary conservation of the allosteric activation of factor VIIa by tissue factor in lamprey.
J Thromb Haemost. 2018 Apr;16(4):734-748. doi: 10.1111/jth.13968. Epub 2018 Mar 12.
7
Tissue factor activates allosteric networks in factor VIIa through structural and dynamic changes.
J Thromb Haemost. 2015 Feb;13(2):262-7. doi: 10.1111/jth.12791. Epub 2014 Dec 12.

引用本文的文献

1
Engineering of a membrane-triggered activity switch in coagulation factor VIIa.
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12454-12459. doi: 10.1073/pnas.1618713114. Epub 2017 Nov 6.
2
Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies.
J Biol Chem. 2015 Mar 13;290(11):6715-30. doi: 10.1074/jbc.M114.630715. Epub 2015 Jan 8.
3
The spatial structure of cell signaling systems.
Phys Biol. 2013 Aug;10(4):045004. doi: 10.1088/1478-3975/10/4/045004. Epub 2013 Aug 2.

本文引用的文献

1
Current status on tissue factor activation of factor VIIa.
Thromb Res. 2010 Apr;125 Suppl 1:S11-2. doi: 10.1016/j.thromres.2010.01.023. Epub 2010 Feb 13.
2
Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa.
FEBS J. 2009 Jun;276(11):3099-109. doi: 10.1111/j.1742-4658.2009.07028.x. Epub 2009 Apr 23.
4
Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies.
J Thromb Haemost. 2008 Feb;6(2):315-22. doi: 10.1111/j.1538-7836.2007.02868.x. Epub 2007 Dec 10.
5
The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking.
J Thromb Haemost. 2007 Jun;5(6):1097-105. doi: 10.1111/j.1538-7836.2007.02435.x.
6
Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa.
Biochem J. 2007 Aug 1;405(3):429-38. doi: 10.1042/BJ20061901.
8
Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange.
J Biol Chem. 2006 Aug 11;281(32):23018-24. doi: 10.1074/jbc.M602968200. Epub 2006 May 10.
9
An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex.
J Biol Chem. 2004 Sep 24;279(39):40445-50. doi: 10.1074/jbc.M405966200. Epub 2004 Jul 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验